News

Recent research and conversations shared at the National Eczema Association expo tackled the link between patient well-being and eczema.

Adopting diversity management is not just a choice but a pressing need in the evolving health care landscape.

A new report delves into the case of a 35-year-old man with ARPC and why dupilumab was utilized for treatment.

James Song, MD, shares a comprehensive guide to what is new, what is now, and what is next in AD treatment.

With the latest advancements in dermatology, there is a great range of treatments available to address the various types of acne scarring.

A recent review found success from a 3-component, simplified habit reversal therapy implemented by dermatologists for BFRBs.

Pyzchiva will be commercialized by Sandoz in the United States.

A recent study demonstrated the benefits and limitations of PatientsLikeMe for patients with atopic dermatitis and other skin conditions.

Dermatology Times asked our readers to share what conferences they are looking forward to in the third quarter of 2024.

Keep up with the latest headlines in dermatology from the past week, including application of AI in dermatology, exposure to forever chemicals through the skin, and more.

In case you missed it, this week we had news about sarecycline's efficacy in periorificial dermatitis, Health Canada's authorization of lebrikizumab for AD, the FDA's investigational new drug clearance of ENS-002 for AD, and more.

Researchers found that the hemp derivative addressed multiple facets of acne pathophysiology and improved acne scarring overall.

Risankizumab outperformed other biologics in real-world psoriasis treatment, achieving higher PASI 90/100 rates and patient satisfaction.

Dermatology Times is looking back on the top stories in dermatology from the month of June.

Learn more about the in-depth topics covered in the June 2024 print issue of Dermatology Times.

Peter Prieto, MD, MPH, shares details of the IOV-COM-202 trial.

Researchers found the assessment accounted for those with moderate impact, allowing clinicians to create improved treatment plans for patients.

Dermatology Times is recapping our top expert interviews from the month of June.

Bradley Burnam discusses results from an in-vivo model of atopic dermatitis.

A recent study found the use of CO2 lasers significantly improved patient quality of life and disease symptoms in the long-term.

Maryanne Makredes Senna, MD, shares insights into the complexities of treating alopecia areata and guidance for clinicians.

Recent research has shed light on public interest of BPO utilizing relative search volume data.

Although like count was down for posts from physicians, researchers also found an increase in share count, indicating a higher rate of reliability.

Ensemble No.2, or ENS-002, is an investigational live biotherapeutic product first detected by Concerto Biosciences using its kChip technology.

An analysis explored the feasibility of directing attention towards the thyroid receptor β as a pathway for creating novel medications to address androgenetic alopecia.

The treatment of vitiligo has advanced from ancient herbal remedies to the first FDA-approved topical, paving the way for improved management and outcomes.

In today’s podcast, Silverberg discusses topical therapeutics for vitiligo and clinical excellence.

The study found that CMT is effective and well-tolerated in treating stable vitiligo, with significant positive correlations between the target area treatment ratio and repigmentation.

Researchers stated the findings highlight the need for integrated dermatological and psychological treatment approaches.

Authorization for Eli Lilly's Ebglyss is based on positive results from the ADvocate 1, ADvocate 2, and ADhere studies.